We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
Read MoreHide Full Article
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. Baxter reports its operating results based on three reportable geographic segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Further, its renal portfolio is for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its first-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 70 cents per share beat the Zacks Consensus Estimate by 12.9% and increased by 20.7% from the year-ago quarter.
Revenues: Baxter posted sales of $2.68 billion, edging past the Zacks Consensus Estimate of $2.62 billion. Revenues increased 4% at constant currency (cc).
Key Stats: The company’s core Renal Care segment recorded sales worth $868 million in the reported quarter, up 4% year over year at cc.
Geographically, US sales registered $1.44 billion, up 4% from the year-ago quarter at cc. EMEA sales came in at $724 million which increased 3% from the year-ago quarter at cc. APAC sales came in at $511 million, up 3% on year-over-year basis at cc.
Major Factors: For the second quarter, Baxter expects sales growth of approximately 5% at cc. Adjusted earnings per share in the second quarter is expected to come within 69-71 cents.
Baxter raised its 2018 guidance. For full year 2018, the company expects sales growth of 5% at cc. Baxter expects adjusted earnings from continuing operations to lie within the range of $2.85-2.93 per share.
Stock Price: Shares have risen roughly 20% in the last year, while the industry has gained 10.8% over the same time frame.
Following the earnings release, share prices inched up 2.2% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. Baxter reports its operating results based on three reportable geographic segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Further, its renal portfolio is for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its first-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 70 cents per share beat the Zacks Consensus Estimate by 12.9% and increased by 20.7% from the year-ago quarter.
Revenues: Baxter posted sales of $2.68 billion, edging past the Zacks Consensus Estimate of $2.62 billion. Revenues increased 4% at constant currency (cc).
Key Stats: The company’s core Renal Care segment recorded sales worth $868 million in the reported quarter, up 4% year over year at cc.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Geographically, US sales registered $1.44 billion, up 4% from the year-ago quarter at cc. EMEA sales came in at $724 million which increased 3% from the year-ago quarter at cc. APAC sales came in at $511 million, up 3% on year-over-year basis at cc.
Major Factors: For the second quarter, Baxter expects sales growth of approximately 5% at cc. Adjusted earnings per share in the second quarter is expected to come within 69-71 cents.
Baxter raised its 2018 guidance. For full year 2018, the company expects sales growth of 5% at cc. Baxter expects adjusted earnings from continuing operations to lie within the range of $2.85-2.93 per share.
Stock Price: Shares have risen roughly 20% in the last year, while the industry has gained 10.8% over the same time frame.
Following the earnings release, share prices inched up 2.2% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>